Visão geral da empresa
A biotechnology enterprise, NervGen Pharma Corp., focuses on the discovery, development, and commercialization of pharmaceutical treatments designed to promote nervous system repair in contexts involving neurotrauma and neurologic disease. The company operates within the Healthcare sector, specifically the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant investment in research and development before potential commercialization. Currently, the firm holds a market capitalization of $337.45M, while specific annual revenue and employee count figures are not publicly disclosed in the available data. This market capitalization indicates that the company is positioned as a mid-cap entity within the biotech landscape, operating with limited historical revenue data that reflects its stage of clinical development rather than established commercial sales.
Saúde financeira
The company reports a Net Income (TTM) of $-25,572,946 and an EBITDA of $-25,201,288, while specific revenue figures are not available for the trailing twelve months. The substantial gap between revenue and net income, combined with the absence of reported revenue, reveals a cost structure dominated by operational expenses related to clinical trials and research activities rather than cost of goods sold, typical for early-stage biopharmaceutical firms. Free Cash Flow stands at $-7,214,422, indicating that the company is burning cash to fund its operations and clinical programs, which limits its immediate financial flexibility without external capital raises. All three margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a metric that indicates the company has not yet generated positive commercial profitability or recognized revenue sufficient to calculate standard margins. Total cash on hand amounts to $11.36M, whereas total debt is $33,225, suggesting the company maintains a highly conservative balance sheet with negligible leverage relative to its liquid assets. The Debt to Equity ratio is listed as N/A due to the lack of equity data in the standard calculation, but the cash position vastly outweighs the debt obligation. The Current Ratio is 0.79, which indicates that the company's short-term liquid assets are insufficient to cover its current liabilities, signaling potential liquidity constraints. Furthermore, the Return on Equity is -820.1% and the Return on Assets is -88.8%, metrics that reveal that management has not yet achieved positive returns on the capital deployed, reflecting the losses inherent in the pre-commercialization phase of the business.
Avaliação de valorização
The Trailing P/E Ratio (TTM) is not available, while the Forward P/E is -20.48, a negative figure that implies the market expects the company to remain unprofitable in the near future or that earnings are not yet realized. The Price to Book ratio is -148.08, indicating a significant negative premium where the market valuation is substantially below the book value, a common characteristic for unprofitable biotech firms with intangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is -12.79, suggesting that traditional valuation multiples are not applicable due to the lack of positive earnings and sales data. The stock's 52-week high is $6.30 and the 52-week low is $1.50, meaning the current trading price sits within a range that reflects significant volatility but remains below the recent peak. The Beta value is 0.99, which indicates that the stock's price volatility moves in line with the broader market, neither significantly amplifying nor dampening the overall market movements.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's early stage where historical growth rates cannot be calculated from prior fiscal years. Since the growth rates are unavailable, it is impossible to determine if earnings are growing faster or slower than revenue, as the firm has not yet transitioned to a revenue-generating model that would allow for such comparisons. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the firm reinvests all available resources and potential earnings back into its research and development pipeline rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on capital markets for funding, as the absence of dividends and the negative financial metrics prioritize long-term clinical milestones over immediate financial returns or shareholder distributions.